Gufic Biosciences Q2 FY27: Revenue at ₹288.4 Cr, PAT at ₹23.5 Cr
Gufic Biosciences reported Q2 FY27 revenue of ₹288.4 crore and PAT of ₹23.5 crore, up from ₹230.4 crore and ₹14.9 crore respectively in Q2 FY26. The company's Indore manufacturing facility is operational and US FDA inspected. Key business segments like hospital injectables, women's health, and botulinum toxin are showing progress.
The announcement provides an update on financial performance and business progress, which are important for investors. However, it does not contain any major strategic shifts or exceptionally high growth figures that would warrant a 'HIGH' impact.
The company reported increased revenue and profit for the quarter compared to the previous year. The operationalization of the Indore facility and progress across various business segments indicate positive growth prospects.
Gufic Biosciences Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a total revenue of ₹288.4 crore for Q2 FY27, an increase from ₹230.4 crore in Q2 FY26. Profit After Tax (PAT) for the quarter stood at ₹23.5 crore, up from ₹14.9 crore in the same period last year.
The company's Indore facility, designed to global regulatory standards including US FDA, EU GMP, and WHO GMP, has commenced commercial production in October 2024. It boasts a significant installed capacity, with 50 million lyophilized vials, 30 million liquid vials, and 72 million ampoules per year.
Key business updates include progress in the hospital injectable platform with launches like AWABAC and focus on dual-chamber bags. The women's health platform is scaling its fertility franchise and prescription-led brands. The botulinum toxin platform is expanding into a full-stack aesthetics platform with planned filler launches and therapeutic applications. The Nutra, Ayurveda & others segment is focusing on chronic care, with the Sallaki range maintaining leadership.
Internationally, Gufic is shifting to an IP-owned, complex-injectable-led market access model. In Q2 FY27, registrations were secured in Saudi Arabia, Azerbaijan, and Chile, with first orders received. The European footprint widened through Gufic Ireland. The company is also focusing on R&D, particularly in peptides and critical API self-reliance, and novel drug delivery systems.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.